Vilazodone

Generic Name
Vilazodone
Brand Names
Viibryd
Drug Type
Small Molecule
Chemical Formula
C26H27N5O2
CAS Number
163521-12-8
Unique Ingredient Identifier
S239O2OOV3
Background

Vilazodone is a novel compound with combined high affinity and selectivity for the 5-hydroxytryptamine (5-HT) transporter and 5-HT(1A) receptors. Vilazodone may also be associated with less sexual dysfunction and weight gain. Vilazodone was given FDA approval on January 21, 2011.

Indication

用于治疗成人重度抑郁症(MDD)。

Associated Conditions
Major Depressive Disorder (MDD)
Associated Therapies
-

Longitudinal Comparative Effectiveness of Bipolar Disorder Therapies

Terminated
Conditions
First Posted Date
2016-09-08
Last Posted Date
2024-03-12
Lead Sponsor
University of New Mexico
Target Recruit Count
1037352
Registration Number
NCT02893371
Locations
🇺🇸

Christophe G Lambert, Albuquerque, New Mexico, United States

A Study of Vilazodone in Pediatric Patients With Major Depressive Disorder

Phase 3
Completed
Conditions
Interventions
First Posted Date
2015-05-06
Last Posted Date
2019-09-11
Lead Sponsor
Forest Laboratories
Target Recruit Count
330
Registration Number
NCT02436239
Locations
🇺🇸

ATP Clinical Research, Costa Mesa, California, United States

🇺🇸

Psychiatric Associates, Overland Park, Kansas, United States

🇺🇸

Pharmsite Research Inc., Baltimore, Maryland, United States

and more 52 locations

Safety and Efficacy of Vilazodone in Pediatric Patients With Major Depressive Disorder (VLZ-MD-22)

First Posted Date
2015-02-26
Last Posted Date
2019-10-01
Lead Sponsor
Forest Laboratories
Target Recruit Count
473
Registration Number
NCT02372799
Locations
🇺🇸

Harmonex Neuroscience Research, Dothan, Alabama, United States

🇺🇸

Woodland International Research Group, INC, Little Rock, Arkansas, United States

🇺🇸

ATP Clinical Research, Costa Mesa, California, United States

and more 56 locations

The Effects of Vilazodone on Glutamate in the Anterior Cingulate Cortex in Anxious Unipolar Depressives

First Posted Date
2014-01-06
Last Posted Date
2016-11-08
Lead Sponsor
Massachusetts General Hospital
Registration Number
NCT02028026
Locations
🇺🇸

Massachusetts General Hospital, Boston, Massachusetts, United States

Switching From Generic Selective Serotonin Reuptake Inhibitors (SSRIs) and Selective Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs) to Three Different Dose Initiation Strategies With Vilazodone

Phase 3
Completed
Conditions
Interventions
First Posted Date
2013-12-19
Last Posted Date
2015-04-16
Lead Sponsor
Duke University
Target Recruit Count
70
Registration Number
NCT02015546
Locations
🇺🇸

Duke University Medical Center / Civitan Building, Durham, North Carolina, United States

Vilazodone for Separation Anxiety Disorder

Phase 4
Completed
Conditions
Interventions
First Posted Date
2013-12-03
Last Posted Date
2018-03-07
Lead Sponsor
New York State Psychiatric Institute
Target Recruit Count
24
Registration Number
NCT01999920
Locations
🇺🇸

New York State Psychiatric Institute, New York, New York, United States

Safety and Efficacy of Vilazodone in Adolescent Patients With Major Depressive Disorder

Phase 3
Completed
Conditions
Interventions
First Posted Date
2013-06-14
Last Posted Date
2019-12-24
Lead Sponsor
Forest Laboratories
Target Recruit Count
529
Registration Number
NCT01878292
Locations
🇺🇸

Forest Investigative Site 054, Baltimore, Maryland, United States

🇺🇸

Forest Investigative Site 034, Oakland Park, Florida, United States

🇺🇸

Forest Investigative Site 030, Roswell, Georgia, United States

and more 49 locations

Does Vilazodone Help With Antidepressant-associated Sexual Dysfunction?

First Posted Date
2013-05-17
Last Posted Date
2016-08-25
Lead Sponsor
Thomas Jefferson University
Target Recruit Count
4
Registration Number
NCT01856127
Locations
🇺🇸

University of Pennsylvania, Philadelphia, Pennsylvania, United States

🇺🇸

University of Virginia, Charlottesville, Virginia, United States

🇺🇸

Thomas Jefferson University, Philadelphia, Pennsylvania, United States

Safety, Efficacy and Tolerability of Vilazodone in (GAD) Generalized Anxiety Disorder

Phase 3
Completed
Conditions
Interventions
First Posted Date
2013-05-01
Last Posted Date
2019-12-18
Lead Sponsor
Forest Laboratories
Target Recruit Count
415
Registration Number
NCT01844115
Locations
🇺🇸

Forest Investigative Site 023, Birmingham, Alabama, United States

🇺🇸

Forest Investigative Site 013, Phoenix, Arizona, United States

🇺🇸

Forest Investigative Site 001, Costa Mesa, California, United States

and more 33 locations

Vilazodone for Corticosteroid-Induced Memory Impairment

First Posted Date
2013-04-10
Last Posted Date
2019-04-11
Lead Sponsor
University of Texas Southwestern Medical Center
Target Recruit Count
24
Registration Number
NCT01828515
Locations
🇺🇸

UT Southwestern Medical Center, Dallas, Texas, United States

© Copyright 2024. All Rights Reserved by MedPath